Gratus Capital’s BioNTech BNTX Stock Holding History

Gratus Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-80,719	Closed	-$12.1M	–	229
2022 Q4	$12.1M	Buy	+80,719	New	+$12.4M	1%	38

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Gratus Capital's BNTX Position: Q1 2023 in Review

Gratus Capital sold out of BioNTech (BNTX) in Q1 2023, closing a stake of 80,719 shares — an estimated $12.1M sold.

Gratus Capital first reported a position in BNTX in Q4 2022 and held it in 1 quarter. The position peaked at $12.1M in Q4 2022. 282 funds tracked by Wall St. Rank hold BNTX as of Q1 2023.

Gratus Capital reported no remaining BioNTech position as of Q1 2023 after selling out during the quarter.
Gratus Capital sold 80,719 BioNTech shares in Q1 2023, an estimated $12.1M.
Gratus Capital first reported a position in BioNTech in Q4 2022 and held it in 1 quarter.
Gratus Capital's BioNTech position peaked at $12.1M in Q4 2022.
282 funds tracked by Wall St. Rank held BioNTech as of Q1 2023.

Based on Gratus Capital's 13F filing for Q1 2023, filed 20 Apr 2023.